WO2000067788A2 - Use of soluble costimulatory molecules to enhance immune responses - Google Patents
Use of soluble costimulatory molecules to enhance immune responses Download PDFInfo
- Publication number
- WO2000067788A2 WO2000067788A2 PCT/US2000/012435 US0012435W WO0067788A2 WO 2000067788 A2 WO2000067788 A2 WO 2000067788A2 US 0012435 W US0012435 W US 0012435W WO 0067788 A2 WO0067788 A2 WO 0067788A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- molecule
- cells
- peptide
- cell
- Prior art date
Links
- 230000000139 costimulatory effect Effects 0.000 title claims abstract description 84
- 230000028993 immune response Effects 0.000 title claims abstract description 56
- 239000000427 antigen Substances 0.000 claims abstract description 107
- 108091007433 antigens Proteins 0.000 claims abstract description 107
- 102000036639 antigens Human genes 0.000 claims abstract description 107
- 238000000034 method Methods 0.000 claims abstract description 95
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 49
- 230000002708 enhancing effect Effects 0.000 claims abstract description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 278
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 158
- 229920001184 polypeptide Polymers 0.000 claims description 100
- 206010028980 Neoplasm Diseases 0.000 claims description 89
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 102000004169 proteins and genes Human genes 0.000 claims description 53
- 235000018102 proteins Nutrition 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 37
- 239000002671 adjuvant Substances 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 230000027455 binding Effects 0.000 claims description 19
- 108060003951 Immunoglobulin Proteins 0.000 claims description 16
- 102000018358 immunoglobulin Human genes 0.000 claims description 16
- 230000005867 T cell response Effects 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000003612 virological effect Effects 0.000 claims description 10
- 230000024932 T cell mediated immunity Effects 0.000 claims description 7
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 230000028996 humoral immune response Effects 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 108010087819 Fc receptors Proteins 0.000 claims description 4
- 102000009109 Fc receptors Human genes 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 201000001531 bladder carcinoma Diseases 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 201000006512 mast cell neoplasm Diseases 0.000 claims description 3
- 208000006971 mastocytoma Diseases 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 238000002649 immunization Methods 0.000 abstract description 65
- 230000003053 immunization Effects 0.000 abstract description 63
- 102000005738 B7 Antigens Human genes 0.000 abstract description 32
- 108010045634 B7 Antigens Proteins 0.000 abstract description 30
- 230000001225 therapeutic effect Effects 0.000 abstract description 24
- 230000000069 prophylactic effect Effects 0.000 abstract description 7
- 239000012678 infectious agent Substances 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 104
- 210000004027 cell Anatomy 0.000 description 100
- 230000004044 response Effects 0.000 description 85
- 210000001744 T-lymphocyte Anatomy 0.000 description 56
- 230000000694 effects Effects 0.000 description 43
- 108020004414 DNA Proteins 0.000 description 32
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 28
- 102000004127 Cytokines Human genes 0.000 description 27
- 108090000695 Cytokines Proteins 0.000 description 27
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 27
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 27
- 238000011282 treatment Methods 0.000 description 27
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 26
- 125000003275 alpha amino acid group Chemical group 0.000 description 26
- 241000700605 Viruses Species 0.000 description 25
- 150000001413 amino acids Chemical class 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 230000009089 cytolysis Effects 0.000 description 22
- 229940037003 alum Drugs 0.000 description 21
- 108020001507 fusion proteins Proteins 0.000 description 21
- 150000007523 nucleic acids Chemical class 0.000 description 21
- 102000037865 fusion proteins Human genes 0.000 description 20
- 102000039446 nucleic acids Human genes 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 238000000338 in vitro Methods 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 19
- 108010074328 Interferon-gamma Proteins 0.000 description 17
- 238000003556 assay Methods 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 102100037850 Interferon gamma Human genes 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 230000004940 costimulation Effects 0.000 description 13
- 230000009696 proliferative response Effects 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 13
- 238000002255 vaccination Methods 0.000 description 13
- 229960005486 vaccine Drugs 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 239000013604 expression vector Substances 0.000 description 12
- 210000002865 immune cell Anatomy 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 230000001404 mediated effect Effects 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 230000004614 tumor growth Effects 0.000 description 12
- 241001529936 Murinae Species 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000036039 immunity Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- -1 ICOS Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 210000001165 lymph node Anatomy 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 108091008874 T cell receptors Proteins 0.000 description 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 239000012707 chemical precursor Substances 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 239000000816 peptidomimetic Substances 0.000 description 8
- 210000004988 splenocyte Anatomy 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 230000036755 cellular response Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102100026445 A-kinase anchor protein 17A Human genes 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- 238000011765 DBA/2 mouse Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101000718019 Homo sapiens A-kinase anchor protein 17A Proteins 0.000 description 6
- 102000011931 Nucleoproteins Human genes 0.000 description 6
- 108010061100 Nucleoproteins Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000006052 T cell proliferation Effects 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 5
- 102100034980 ICOS ligand Human genes 0.000 description 5
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 5
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 5
- 102000000743 Interleukin-5 Human genes 0.000 description 5
- 108010002616 Interleukin-5 Proteins 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000002516 postimmunization Effects 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 230000006023 anti-tumor response Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- 239000002612 dispersion medium Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 description 4
- 210000004986 primary T-cell Anatomy 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000011191 terminal modification Methods 0.000 description 4
- 229940030325 tumor cell vaccine Drugs 0.000 description 4
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 102000003816 Interleukin-13 Human genes 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 102000043131 MHC class II family Human genes 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 230000009435 amidation Effects 0.000 description 3
- 238000007112 amidation reaction Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000002788 anti-peptide Effects 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 210000004976 peripheral blood cell Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000002708 random mutagenesis Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 239000012646 vaccine adjuvant Substances 0.000 description 3
- 229940124931 vaccine adjuvant Drugs 0.000 description 3
- 230000005730 ADP ribosylation Effects 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101710093458 ICOS ligand Proteins 0.000 description 2
- 241001500351 Influenzavirus A Species 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108010028921 Lipopeptides Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000003070 absorption delaying agent Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000006251 gamma-carboxylation Effects 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 238000000302 molecular modelling Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 239000002644 phorbol ester Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 101150098072 20 gene Proteins 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102000015404 Amino Acid Receptors Human genes 0.000 description 1
- 108010025177 Amino Acid Receptors Proteins 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000004858 Growth differentiation factor-9 Human genes 0.000 description 1
- 108090001086 Growth differentiation factor-9 Proteins 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101710126321 Pancreatic trypsin inhibitor Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000003091 anti-genotoxic effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940100994 interleukin-7 Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 208000016021 phenotype Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000003725 proteoliposome Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- T cells In order for T cells to respond to foreign proteins, two signals must be provided by antigen-presenting cells (APCs) to resting T lymphocytes (Jenkins, M. and Schwartz, R. (1987) J. Exp. Med. 165, 302-319; Mueller, D.L., et al. (1990) J. Immunol. 144, 3701-3709).
- the first signal which confers specificity to the immune response, is transduced via the T cell receptor (TCR) following recognition of foreign antigenic peptide presented in the context of the major histocompatibility complex (MHC).
- TCR T cell receptor
- MHC major histocompatibility complex
- costimulation induces T cells to proliferate and become functional (Lenschow et al. 1996. Annu. Rev. Immunol.
- Costimulation is neither antigen-specific, nor MHC restricted and is thought to be provided by one or more distinct cell surface molecules expressed by APCs (Jenkins, M.K., et al. 1988 J. Immunol. 140, 3324-3330; Linsley, P.S., et al. 1991 J. Exp. Med. 173, 721-730; Gimmi, CD., et al., 1991 Proc. Natl. Acad. Sci. USA. 88, 6575-6579; Young, J.W., et al. 1992 J. Clin. Invest. 90, 229-237; Koulova, L., et al. 1991 J. Exp. Med. L73, 759-762; Reiser, H., et al. 1992 Proc. Natl. Acad. Sci. USA. 89, 271-275; van-Seventer, G.A., et al.
- CD80 and CD86 (B7-2) proteins, expressed on APCs, are critical costimulatory molecules (Freeman et al. 1991. J. Exp. Med. 174:625; Freeman et al. 1989 J. Immunol. 143:2714; Azuma et al. 1993 Nature 366:76; Freeman et al. 1993. Science 262:909).
- B7-2 appears to play a predominant role during primary immune responses, while B7- 1 , which is upregulated later in the course of an immune response, may be important in prolonging primary T cell responses or costimulating secondary T cell responses (Bluestone. 1995. Immunity. 2:555).
- CD28 One ligand to which B7-1 and B7-2 bind, CD28, is constitutively expressed on resting T cells and increases in expression after activation. After signaling through the T cell receptor, ligation of CD28 and transduction of a costimulatory signal induces T cells to proliferate and secrete IL-2 (Linsley, P.S., et al. 1991 J. Exp. Med. 173, 721-730; Gimmi, CD., et al. 1991 Proc. Natl. Acad. Sci. USA. 88. 6575-6579; June, C.H., et al. 1990 Immunol. Today. U, 211-6; Harding, F.A., et al. 1992 Nature. 356, 607-609).
- CTLA4 A second ligand, termed CTLA4 (CD152) is homologous to CD28 but is not expressed on resting T cells and appears following T cell activation (Brunet, J.F., et al., 1987 Nature 328, 267-270). In contrast to CD28, CTLA4 appears to be critical in negative regulation of T cell responses (Waterhouse et al. 1995. Science 270:985). Blockade of CTLA4 has been found to remove inhibitory signals, while aggregation of CTLA4 has been found to provide inhibitory signals that downregulate T cell responses (Allison and Krummel. 1995. Science 270:932).
- the present invention provides methods for enhancing immune responses by manipulating the costimulatory pathway.
- the subject methods are particularly effective in augmenting responses to tumor antigens and antigens from infectious agents. - _y
- the present invention is based, at least in part, on the discovery that soluble forms of costimulatory molecules can prophylactically and therapeutically enhance immune responses. This enhancement is seen despite the fact that the soluble costimulatory molecules of the invention are not administered on a solid phase (e.g., are not administered on a cell) and are administered in the absence of a cross-linking agent. These findings are particularly surprising in light of the teaching that soluble forms of B7-1 and B7-2 molecules fail to generate costimulatory responses (Hayden et al. 1996. Tissue Antigens. 48:242; U.S. patent 5,580,756).
- the present invention provides methods of prophylactically enhancing an immune response by a subject to an antigen by administering a soluble composition comprising an extracellular domain of a costimulatory molecule, such that the immune response of the subject to the antigen is enhanced.
- the invention provides methods of therapeutically enhancing an immune response by a subject to an antigen by administering a soluble composition comprising an extracellular domain of a costimulatory molecule, such that the immune response of the subject to the antigen is enhanced.
- the costimulatory molecule is selected from the group consisting of B7-1 and B7-2.
- the invention provides a method of enhancing the costimulatory molecule
- CD8+ T cell response to a class I restricted antigen in a subject by administering a first agent comprising a class I restricted antigen or fragment thereof and a soluble composition comprising an extracellular domain of a B7 molecule, such that upon administration to the subject the CD8+ T cell response to a class I restricted antigen is enhanced.
- the methods further comprise administering a class II restricted antigen to the subject.
- the methods further comprises administering an adjuvant to the subject.
- the B7 molecule is a B7-1 molecule.
- the B7 molecule is a B7-2 molecule.
- the costimulatory molecule is monospecific.
- the costimulatory molecule is dimeric and bivalent.
- the soluble costimulatory molecule is monospecific and dimeric and bivalent.
- B7 molecule is fused to a second protein or polypeptide comprising a portion of an immunoglobulin molecule.
- the portion of the immunoglobulin molecule comprises cysteine residues.
- the portion of the immunoglobulin molecule comprises the hinge, CH2 and CH3 regions of a human immunoglobulin molecule.
- the portion of the immunoglobulin molecule comprises the hinge, CHI, CH2 and CH3 regions of a human immunoglobulin molecule.
- the immunoglobulin molecule has been modified to reduce complement fixation and/or Fc receptor binding.
- the antigen is a tumor cell antigen.
- the subject has a cancer of a type selected from the group consisting of: colon cancer, breast cancer, prostate cancer, renal cell cancer, leukemia, lymphoma, melanoma, mastocytoma, sarcoma, and bladder carcinoma.
- the antigen is an antigen selected from the group consisting of: a bacterial antigen, a viral antigen, and a parasite antigen.
- the immune response is a cellular immune response.
- the immune response is a humoral immune response.
- Figure 1 shows antigen specific proliferative response of cells from mice immunized with Class II-restricted peptides with or without coadministration of B7-2Ig (lOO ⁇ g).
- Figure 2 shows that cells from mice that had received a single B7-2Ig treatment at the time of primary immunization had greater proliferative responses following a second immunization than cells from mice that never received B7-2Ig.
- the data are from replicate experiments.
- Figure 3 shows that B7-2Ig coadministration enhances the CTL response to immunization with class I restricted peptide.
- Figure 4 shows the CTL response of mice immunized with class I restricted peptide in the presence or absence of class II restricted peptide and B7-2 Ig treatment.
- Figure 5 shows that B7-IgG provides a co-stimulatory signal for in vitro proliferation and lymphokine secretion in splenocytes.
- Figure 6 shows that B7Ig is effective as an adjuvant in a prophylactic tumor vaccine model.
- Figure 7 shows therapeutic vaccination of mice with irradiated P815 tumor cells mixed with B7-1- or B7-2-IgG induces tumor regression and prolonged survival.
- Figure 8 shows that immunization of mice with B7-IgG as an adjuvant for a therapeutic irradiated tumor cell vaccine is effective in several different mouse tumor models.
- Figure 9 shows the anti-tumor effect of therapeutic administration of B7-IgG alone in mice is comparable to its effect as vaccine adjuvant.
- FIG. 10 shows that T or B cells are required for B7-IgG-mediated anti-tumor activity.
- FIG 11 shows that CD8+, but not CD4+, T cells are required to mediate B7-IgG anti- tumor activity.
- Figure 12 shows that B7-IgG therapy of established tumors is independent of host IFN- ⁇ .
- the instant invention provides improved methods of enhancing immune responses by administration of soluble costimulatory molecules (e.g., an extracellular domain of a B7 molecule, or a B7 fusion protein) to thereby enhance immune responses.
- soluble costimulatory molecules e.g., an extracellular domain of a B7 molecule, or a B7 fusion protein
- the soluble costimulatory molecules are administered without a cross-linking agent, yet, surprisingly, stimulate T cell responses.
- the instant methods result in an increased level of costimulation than costimulatory molecules presented on a surface, e.g.. costimulatory molecules on the surface of a cell.
- prophylactically includes the administration of a costimulatory molecule prior to or simultaneously with exposure to the antigen against which the immune response is to be developed, augmented, and/or enhanced.
- the term "therapeutically" includes the administration of a costimulatory molecule to treat an existing or ongoing infection or disease (e.g., cancer or a viral or bacterial infection) which would benefit by treatment with a costimulatory molecule.
- a costimulatory molecule is administered at a point in time after exposure to the antigen against which the immune response is to be developed, augmented, and/or enhanced. It will be understood that therapeutic treatment with a costimulatory molecule may have other beneficial effects on the immune response of a subject, e.g., that are not specific for that particular antigen.
- the term "immune cell” includes cells that are of hematopoietic origin and play a role in an immune response. Immune cells include lymphocytes, such as B cells and T cells; natural killer cells: myeloid cells, such as monocytes, macrophages, eosinophils, mast cells, basophils, and granulocytes.
- the term " immune response” includes T and/or B cell responses, i.e.. cellular and/or humoral immune responses.
- the claimed methods can be used to reduce T helper cell responses.
- the claimed methods can be used to reduce cytotoxic T cell responses.
- the claimed methods can be used to reduce both primary and secondary immune responses.
- the immune response of a subject can be determined by, for example, assaying antibody production, immune cell proliferation, the release of cytokines, the expression of cell surface markers, cytotoxicity, etc.
- costimulate with reference to activated immune cells includes the ability of a costimulatory molecule to provide a second, non- activating receptor mediated signal (a "costimulatory signal") that induces proliferation or effector function.
- a costimulatory signal can result in cytokine secretion, e.g., in a T cell that has received a T cell-receptor-mediated signal.
- costimulatory molecule includes molecules which are present on antigen presenting cells (e.g., B7-1, B7-2, B7RP-1 (Yoshinaga et al. 1999. Nature 402:827), B7h (Swallow et al. 1999. Immunity.
- B7 molecules bind to costimulatory receptors (e.g., CD28, CTLA4, ICOS (Hutloff et al. 1999. Nature 397:263), B7h ligand (Swallow et al. 1999. Immunity. 11 :423) and/or related molecules) on T cells.
- costimulatory receptors e.g., CD28, CTLA4, ICOS (Hutloff et al. 1999. Nature 397:263), B7h ligand (Swallow et al. 1999. Immunity. 11 :423) and/or related molecules.
- B7 or “B7 molecule” includes naturally occurring B7-1 molecules, B7-2 molecules, B7RP-1 molecules (Yoshinaga et al. 1999. Nature 402:827), B7h molecules (Swallow et al. 1999. Immunity. 11 :423), structurally related molecules, fragments of such molecules, and/or functional equivalents thereof.
- equivalent is intended to include amino acid sequences encoding functionally equivalent costimulatory molecules having an activity of a B7 molecule, e.g., the ability to bind to the natural ligand(s) of B7 on immune cells, such as CTLA4, ICOS, and/or CD28 on T cells, and/or the ability to modulate immune cell costimulation.
- polypeptide(s) refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds.
- Polypeptide(s) refers to both short chains, commonly referred to as peptides. oligopeptides and oligomers and to longer chains generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene encoded amino acids.
- Polypeptide(s) include those modified either by natural processes, such as processing and other post-translational modifications, but also by chemical modification techniques. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature, and they are well known to those of skill in the art.
- Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains, and the amino or carboxyl termini.
- Modifications include, for example, acetylation, acylation, ADP- ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, glycosylation, lipid attachment, sulfation, gamma- carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, se
- Polypeptides may be branched or cyclic, with or without branching. Cyclic, branched and branched circular polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well.
- an "isolated polypeptide” or “isolated protein” refers to a polypeptide or protein that is substantially free of other polypeptides, proteins, cellular material and culture medium when isolated from cells or produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.
- an “isolated” or “purified” polypeptide or biologically active portion thereof is substantially free of cellular material or other contaminating polypeptides from the cell or tissue source from which the B7 polypeptide is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized.
- the language “substantially free of cellular material” includes preparations of B7 polypeptide in which the polypeptide is separated from cellular components of the cells from which it is isolated or recombinantly produced.
- the language "substantially free of cellular material” includes preparations of B7 polypeptide having less than about 30% (by dry weight) of non- B7 polypeptide (also referred to herein as a "contaminating polypeptide"), more preferably less than about 20% of non- B7 polypeptide, still more preferably less than about 10% of non- B7 polypeptide, and most preferably less than about 5% non- B7 polypeptide.
- non- B7 polypeptide also referred to herein as a "contaminating polypeptide”
- contaminating polypeptide also referred to herein as a "contaminating polypeptide”
- the B7 polypeptide or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%. and most preferably less than about 5% of the volume of the polypeptide preparation.
- the language “substantially free of chemical precursors or other chemicals” includes preparations of B7 polypeptide in which the polypeptide is separated from chemical precursors or other chemicals that are involved in the synthesis of the polypeptide.
- the language “substantially free of chemical precursors or other chemicals” includes preparations of B7 polypeptide having less than about 30% (by dry weight) of chemical precursors or non- B7 chemicals, more preferably less than about 20% chemical precursors or non- B7 chemicals, still more preferably less than about 10% chemical precursors or non- B7 chemicals, and most preferably less than about 5% chemical precursors or non- B7 chemicals.
- B7 nucleic acid molecules and polypeptides are "naturally occurring.”
- a "naturally-occurring" molecule refers to an B7 molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural B7 polypeptide).
- naturally or non-naturally occurring variants of these polypeptides and nucleic acid molecules which retain the same functional activity, e.g., the ability to modulate adaptation to stress and/or virulence in a microbe.
- Such variants can be made, e.g., by mutation using techniques that are known in the art. Alternatively, variants can be chemically synthesized.
- variant(s) includes nucleic acid molecules or polypeptides that differ in sequence from a reference nucleic acid molecule or polypeptide, but retains its essential properties. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference nucleic acid molecule. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical.
- a variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, and/or deletions in any combination.
- a variant of a nucleic acid molecule or polypeptide may be naturally occurring, such as an allelic variant, or it may be a variant that is not known to occur naturally.
- Non-naturally occurring variants of nucleic acid molecules and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans.
- the B7 polypeptides described herein are also meant to include equivalents thereof.
- variants can be made, e.g., by mutation using techniques that are known in the art.
- variants can be chemically synthesized.
- mutant forms of B7 polypeptides which are functionally equivalent, e.g., have the ability to bind to CTLA4 and/or CD28
- Mutations can include, e.g., at least one of a discrete point mutation which can give rise to a substitution, or by at least one deletion or insertion.
- random mutagenesis can be used. Mutations can also be made by random mutagenesis or using cassette mutagenesis.
- telomere mutagenesis can be used.
- Megaprimer PCR can be used (O.H. Landt, 1990. Gene 96:125-128).
- the term "enhancing an immune response” includes increasing T and/or B cell responses, i.e., cellular and/or humoral immune responses, by treatment of a subject using the claimed methods.
- the claimed methods can be used to enhance T helper cell responses.
- the claimed methods can be used to enhance cytotoxic T cell responses.
- the claimed methods can be used to enhance both primary and secondary immune responses.
- the claimed methods increase the immune response by a subject when compared to the immune response by an untreated subject or a subject not treated using the claimed methods.
- An increase in an immune response can be shown, e.g., by an increased response of immune cells from the subject to the antigen upon treatment with the claimed methods.
- the immune response of a subject can be determined using a variety of in vitro or in vivo measurements of immune cell activation, for example, assaying antibody production, immune cell proliferation, the release of cytokines, the expression of cell surface markers, cytotoxicity, etc.
- the term "soluble” includes molecules, e.g., costimulatory molecules, which are not cell associated. Soluble costimulatory molecules retain the function of the cell-associated molecules from which they are derived, i.e., they are capable of binding to their cognate ligands on T cells and mediating signal transduction via a CD28 and/or CTLA4 molecule on a T cell, however, they are in soluble form, i.e., are not membrane bound.
- the soluble compositions comprise an extracellular domain of a B7 molecule.
- extracellular domain of a costimulatory molecule includes a portion of a costimulatory molecule which, in the cell-associated form of the costimulatory molecule, is extracellular.
- the extracellular domain of a costimulatory molecule comprises an extracellular domain of a B7 molecule.
- a B7 extracellular domain includes the portion of a costimulatory molecule which mediates binding to CD28 and/or CTLA4.
- the human B7-1 extracellular domain comprises from about amino acid 1 to about amino acid 208 of the mature form of B7-1 (SEQ ID NO:l) and the human B7-2 extracellular domain comprises from about amino acid 24 to about amino acid 245 of the mature form of B7- 2 (SEQ ID NO:2).
- a soluble costimulatory molecule comprises an extracellular domain of a B7 molecule and further comprises a signal sequence.
- class I restricted antigen includes antigens which bind to the major histocompatibility complex (MHC) class I groove and which are presented to T cells in the context of MHC class I molecules. Class I restricted antigens primarily stimulate CD8 + T cells.
- class II restricted antigen includes antigens which bind to the MHC class II groove and are presented to T cells in the context of MHC class II molecules. Class II restricted antigens primarily stimulate CD4+ T cells.
- the term "adjuvant” includes agents which potentiate the immune response to an antigen. Adjuvants can be administered in conjunction with costimulatory molecules to additionally augment the immune response.
- the term “monospecific” includes soluble costimulatory molecules which have only one specificity, i.e., they specifically bind to their cognate ligand, e.g., CD28 or CTLA4 on T cells. Such monospecific agents have not been engineered to include additional specificities and, thus, do not bind in a targeted manner to other cell surface molecules.
- oligospecific includes soluble costimulatory molecules having more than one specificity, e.g., having an additional specificity for a molecule other than a B7 ligand, e.g., a specificity for a cell surface molecule, such as a tumor cell antigen or a T cell receptor.
- bivalent includes soluble costimulatory molecules that have two binding sites for interaction with their cognate ligand, e.g., CD28 and/or CTLA4 per soluble costimulatory molecule.
- dimeric includes soluble forms that are present as homodimers. i.e.. as a unit comprised of two identical subunits which are joined together, e.g., by disulfide bonds.
- multimeric includes soluble forms having more than two subunits.
- the B7 antigens are a family of costimulatory molecules found on the surface of B lymphocytes, professional antigen presenting cells (e.g., monocytes, dendritic cells.
- Langerhans cells and cells which present antigen to immune cells (e.g., keratinocytes, endothelial cells, astrocytes, fibroblasts, oligodendrocytes).
- costimulatory molecules bind either CTLA4, CD28, and/or ICOS on the surface of T cells or other known or as yet undefined receptors on immune cells.
- the members of this family of costimulatory molecules are capable of providing costimulation to activated T cells to thereby induce T cell proliferation and/or cytokine secretion.
- B7 genes cDNA
- B7 genes cDNA
- human and mouse see, for example, Freeman, G.J. et al. (1993) Science 262:909-911 ;
- Nucleotide sequences of costimulatory molecules are known in the art and can be found in the literature or on a database such as GenBank. See, for example, B7-2 (Freeman et al. 1993 Science. 262:909 or GenBank Accession numbers P42081 or
- costimulatory molecule also includes non-naturally occurring forms, e.g., variants or mutant forms of costimulatory molecules which retain the function of a costimulatory molecule, e.g., the ability to bind to cognate counter receptor.
- DNA sequences capable of hybridizing to DNA encoding a B7 molecule, under conditions that avoid hybridization to non-costimulatory molecule genes, can be used to make antiB7 antibodies.
- DNA sequences which retain sequence identity over regions of the nucleic acid molecule which encode protein domains which are important in costimulatory molecule function, e.g., binding to other costimultory molecules, can be used to produce costimulatory proteins which can be used as immunogens.
- nonnaturally occurring costimulatory molecules have significant (e.g., greater than 70%, preferably greater than 80%, and more preferably greater than 90-95%) amino acid identity with a naturally occurring amino acid sequence of a costimulatory molecule extracellular domain.
- amino acid sequences comprising an extracellular domains of costimulatory molecules of different species, e.g., mouse and human, can be aligned and conserved (e.g., identical) residues noted. This can be done, for example, using any standard alignment program, such as MegAlign (DNA STAR). Such alignment programs are described in more detail below. Such conserved or identical residues are likely to be necessary for proper binding of costimulatory molecules to their receptors and are, thus, not likely to be amenable to alteration.
- the regions of the B7-1 molecule which are important in mediating the functional interaction with CD28 and CTLA4 have been identified by mutation.
- peptides having an activity of B7 can be produced using standard techniques.
- Host cells transfected to express peptides can be any procaryotic or eucaryotic cell.
- a peptide having B7 activity can be expressed in bacterial cells such as E. coli, insect cells (baculovirus), yeast, or mammalian cells such as Chinese hamster ovary cells (CHO) and NSO cells.
- suitable host cells and expression vectors may be found in Goeddel, (1990) supra or are known to those skilled in the art. Examples of vectors for expression in yeast S. cerivisae include pYepSecl (Baldari. et al, (1987) Embo J.
- Baculovirus vectors available for expression of proteins in cultured insect cells include the pAc series (Smith et a , (1983) Mol. Cell Biol. 3:2156-2165) and the pVL series (Lucklow, V.A., and Summers, M.D., (1989) Virology 170:31-39).
- COS cells Gluzman, Y., (1981) Cell 23:175-182
- pCDM8 Seed, B., (1987) Nature 329:840
- CHO dhfr" Chinese Hamster Ovary
- pMT2PC Kaufman et al ( 1987), EMBO J. 6: 187- 195
- a preferred cell line for production of recombinant protein is the NSO myeloma cell line available from the ECACC (catalog #85110503) and described in Galfre, G. and Milstein, C.
- Vector DNA can be introduced into mammalian cells via conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofectin, or electroporation. Suitable methods for transforming host cells can be found in Sambrook et aL (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory textbooks. When used in mammalian cells, the expression vector's control functions are often provided by viral material.
- B7 molecules for making the soluble B7 molecules for use in the instant methods can be derived from any mammalian species, and are preferably human.
- the nucleotide sequences of B7 molecules from several sources are known in the art.
- the complete DNA sequence of human B7-1 (CD80) has the GenBank accession number M27533 and was published by Freeman et al. in 1989 in J. Immunol. 143:2714.
- the complete cDNA sequence of human B7-2 (CD86) has the GenBank accession number L25259 and was published by Freeman et al. in Science in 1993. 262;9090 or Azuma et al. Nature. 1993. 366:76. (See also WO 96/40915 for the sequence of both B7-1 and B7-2).
- the nucleotide sequence of human B7-1 and human B7-2 are also shown in SEQ ID Nos: 1 and 2 (B7-1) and SEQ Nos. 3 and 4 (B7-2).
- a sequence can be determined by isolating a B7 nucleic acid molecule from a desired source based on the ability of the sequence to hybridize to the known , e.g., human B7 sequences.
- B7 molecules can be detected by their ability to hybridize under high or low stringency conditions to a known nucleic acid molecule which encodes a peptide having B7 activity.
- the salt concentration in the wash step can be selected from a low stringency of about 2.0 x SSC at 50°C to a high stringency of about 0.2 x SSC at 50°C.
- the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22°C, to high stringency conditions, at about 65°C
- the B7 molecules are human B7 molecules.
- the soluble costimulatory molecule is derived from a naturally occurring B7-1 or B7-2 molecule.
- Polypeptides having an activity of a B7 molecule, as described herein, and having a sequence which differs from a naturally occurring B7 molecule due to degeneracy in the genetic code can also be expressed in soluble form and are also within the scope of the invention.
- Such nucleic acids encode polypeptides which are functionally equivalent to B7, (e.g., a polypeptide having B7 activity) but differ in sequence from the sequence of B7-1 or B7-2 known in the art. For example, a number of amino acids are designated by more than one triplet.
- Codons that specify the same amino acid may occur due to degeneracy in the genetic code.
- DNA sequence polymorphisms within the nucleotide sequence of a B7 molecule may result in "silent" mutations in the DNA which do not affect the amino acid encoded.
- DNA sequence polymorphisms that do lead to changes in the amino acid sequences of the B7 antigen will exist within a population.
- nucleotides up to about 3-4% of the nucleotides
- nucleic acids encoding peptides having the activity of a novel B lymphocyte antigen may exist among individuals within a population due to natural allelic variation.
- nucleotide variations and resulting amino acid polymorphisms are also within the scope of the invention.
- B7 molecules within the scope of the invention can be made using art recognized techniques.
- a soluble costimulatory molecule is a modified form of B7-1 or B7-2 which retains the function of a B7 costimulatory molecule, i.e., is functionally identical.
- the DNA sequence of a B lymphocyte antigen can be modified by genetic techniques to produce proteins or polypeptides with altered amino acid sequences. Such sequences are considered within the scope of the present invention, where the expressed polypeptide is capable of binding to CTLA4 and/or CD28 and modulating T cell mediated immune responses and immune function.
- mutations can be introduced into a DNA molecule by any one of a number of methods, including those for producing simple deletions or insertions, systematic deletions, insertions or substitutions of clusters of bases or substitutions of single bases, to generate variants or modified equivalents of B lymphocyte antigen DNA.
- changes in B7-1 or B7-2 cDNA sequences are preferably obtained by site-directed mutagenesis.
- Site directed mutagenesis systems are well known in the art. Protocols and reagents can be obtained commercially from Amersham International PLC,
- Modified polypeptides having an activity of a B7 molecule i.e., the ability to bind to the natural ligand(s) of a B7 molecule and modulate T cell mediated immune responses, as evidenced by, for example, cytokine production and/or T cell proliferation by T cells that have received a primary activation signal are considered within the scope of the invention.
- Another example of modification of a peptide having the activity of a B7 molecule is substitution of cysteine residues preferably with alanine, serine, threonine, leucine or glutamic acid residues to minimize dimerization via disulfide linkages.
- amino acid side chains of a peptide having B7 activity can be chemically modified.
- Another modification is cyclization of the peptide.
- polypeptides having B7 activity can be modified to incorporate one or more polymorphisms in the amino acid sequence of the antigen resulting from any natural allelic variation.
- D- amino acids, non-natural amino acids, or non-amino acid analogs can be substituted or added to produce a modified protein within the scope of this invention.
- the peptides can be modified using polyethylene glycol (PEG) according to the method of
- Preferred B7 polypeptides have B7 activity and at least about 60% identity, preferably at least about 70% identity, and more preferably at least about 80% identity with a naturally occurring B7 amino acid sequence.
- Polypeptides having B7 activity and at least about 90%, preferably at least about 95%, and more preferably at least about 98-99% identity with naturally occurring B7 molecule are also within the scope of the invention.
- amino acid "identity" at a given position refers to two peptides having the same amino acids at corresponding positions when the amino acid sequences of the peptides are aligned. When a position in the compared sequences is occupied by the same amino acid, then the molecules are identical at that position.
- a degree (or percentage) of identity between sequences is a function of the number of matching or identical positions shared by the sequences.
- the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, 5, or 4 and a length weight of 1 , 2, 3, 4, 5, or 6.
- the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at http://www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5. or 6.
- the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
- the nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences.
- Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10.
- Gapped BLAST can be utilized as described in Altschul et al, (1997) Nucleic Acids Res. 25(17):3389-3402.
- the default parameters of the respective programs e.g., XBLAST and NBLAST
- XBLAST and NBLAST See http://www.ncbi.nlm.nih.gov.
- At least a portion of an extracellular domain of a B7 molecule is defined as an amino acid sequence comprising entire extracellular domain sequence of B7 or a portion thereof which encodes a polypeptide having an activity (i.e., the ability to bind to the natural ligand(s) of B7 on immune cells, such as binding to CTLA4 and/or CD28 on T cells).
- a peptide having B7 activity binds CTLA4 and/or CD28 and modulates a T cell mediated immune response, as evidenced by. for example, binding to these ligands or by inducing cytokine production and/or proliferation by T cells that have received a primary activation signal as shown in the appended Examples.
- "at least a portion of an extracellular domain of a B7 molecule” includes a polypeptide comprising the entire extracellular portion of a human B7 antigen (e.g., approximately amino acid residues 1-208 of the sequence of B7-1 or approximately amino acids 24-245 of the sequence of B7-2) which can be used to bind CTLA4 and/or CD28.
- a human B7 antigen e.g., approximately amino acid residues 1-208 of the sequence of B7-1 or approximately amino acids 24-245 of the sequence of B7-2
- B7 polypeptides comprising only naturally-occurring amino acids
- B7 peptidomimetics are also provided.
- Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs with properties analogous to those of the template peptide. These types of non-peptide compound are termed "peptide mimetics” or “peptidomimetics” (Fauchere, J. (1986) Adv. Drug Res. 15: 29; Veber and Freidinger (1985) TINS p.392; and Evans et al. (1987) J. Med. Chem 30: 1229, which are incorporated herein by reference) and are usually developed with the aid of computerized molecular modeling.
- Peptide mimetics that are structurally similar to therapeutically useful peptides may be used to produce an equivalent therapeutic or prophylactic effect.
- peptide mimetics may have significant advantages over polypeptide embodiments, including, for example: more economical production, greater chemical stability, enhanced pharmacological properties (half-life, absorption, potency, efficacy, etc.), altered specificity (e.g., a broad-spectrum of biological activities), reduced antigenicity, and others.
- Labeling of peptidomimetics usually involves covalent attachment of one or more labels, directly or through a spacer (e.g., an amide group), to non-interfering position(s) on the peptidomimetic that are predicted by quantitative structure-activity data and/or molecular modeling.
- a spacer e.g., an amide group
- non-interfering positions generally are positions that do not form direct contacts with the macromolecules(s) to which the peptidomimetic binds to produce the therapeutic effect.
- Derivitization (e.g., labelling) of peptidomimetics should not substantially interfere with the desired biological or pharmacological activity of the peptidomimetic.
- Systematic substitution of one or more amino acids of an B 7 amino acid sequence with a D-amino acid of the same type may be used to generate more stable peptides.
- constrained peptides comprising an B7 amino acid sequence or a substantially identical sequence variation may be generated by methods known in the art (Rizo and Gierasch (1992) Ann. Rev. Biochem. 61 : 387, incorporated herein by reference); for example, by adding internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.
- polypeptides corresponding to B7 peptide sequences and sequence variants thereof can, without undue experimentation, produce polypeptides corresponding to B7 peptide sequences and sequence variants thereof.
- Such polypeptides may be produced in prokaryotic or eukaryotic host cells by expression of polynucleotides encoding an B7 peptide sequence, frequently as part of a larger polypeptide.
- such peptides may be synthesized by chemical methods.
- Peptides can be produced, e.g., by direct chemical synthesis. Peptides can be produced as modified peptides, with nonpeptide moieties attached by covalent linkage to the N-terminus and/or C-terminus. In certain preferred embodiments, either the carboxy-terminus or the amino-terminus, or both, are chemically modified. The most common modifications of the terminal amino and carboxyl groups are acetylation and amidation, respectively. Amino-terminal modifications such as acylation (e.g., acetylation) or alkylation (e.g., methylation) and carboxy-terminal-modifications such as amidation, as well as other terminal modifications, including cyclization, may be incorporated into various embodiments of the invention.
- acylation e.g., acetylation
- alkylation e.g., methylation
- carboxy-terminal-modifications such as amidation, as well as other terminal modifications, including cyclization
- an B7 "chimeric polypeptide" or “fusion polypeptide” comprises an B7 polypeptide operatively linked to a non- B7 polypeptide.
- B7 polypeptide refers to a polypeptide having an amino acid sequence corresponding to B7 polypeptide
- a non-B7 polypeptide refers to a polypeptide having an amino acid sequence corresponding to a polypeptide which is not substantially homologous to the B7 polypeptide, e.g., a polypeptide which is different from the B7 polypeptide and which is derived from the same or a different organism.
- the B7 polypeptide can correspond to all or a portion of an B7 polypeptide.
- an B7 fusion polypeptide comprises at least one biologically active portion of an B7 polypeptide.
- the term "operatively linked" is intended to indicate that the B7 polypeptide and the non-B7 polypeptide are fused in- frame to each other.
- the non-B7 polypeptide can be fused to the N-terminus or C- terminus of the B7 polypeptide.
- Preferred nucleic acid fragments encode B7 polypeptides of at least about
- fragments are at least about 200 amino acids in length, e.g, comprise an entire extracellular domain of a B7 molecule.
- a number of processes can be used to generate fragments of an isolated DNA sequence. Small subregions or fragments of the nucleic acid encoding the B7-1 or B7-2 proteins, for example 1-30 bases in length, can be prepared by standard, synthetic organic chemical means. The technique is also useful for preparation of primers for use in the generation of larger synthetic fragments of B7 DNA.
- PCR polymerase chain reaction
- a DNA can be synthesized which does not encode the transmembrane and cytoplasmic regions of the protein.
- This DNA molecule can be ligated into an appropriate expression vector and introduced into a host cell such as CHO, where the B7 protein fragment is synthesized and secreted. The B7 protein fragment can then readily be obtained from the culture media.
- a nucleic acid molecule encoding at least a portion of a B7 molecule, such as an extracellular domain portion which is lacking the transmembrane portion of the molecule is placed in an expression vector and is expressed by a host cell such that the B7 molecule is not expressed on the surface of the cell.
- cDNA encoding an extracellular domain of a B7 molecule can be synthesized using the polymerase chain reaction (U.S. patent 4,683,202) using primers derived from the published sequence of B7-1 or B7-2 (see Freeman et al., J. Immunol. 1989. 143:2714 or Science. 1993. 262:9090). The resulting cDNA sequences can then be assembled into a eukaryotic or prokaryotic expression vector and the vector can be used to direct the synthesis of an extracellular domain of B7 by appropriate host cells, for example COS or CHO cells.
- the expression vector includes a DNA encoding a peptide having an activity of a B7 antigen and a DNA encoding a second polypeptide.
- the second polypeptide is preferably not derived from a costimulatory molecule.
- a B7 chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation.
- the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers.
- PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al. John Wiley & Sons: 1992).
- many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide).
- a B7-encoding nucleic acid molecule can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the B7 protein.
- hexa-histidine can be added to the peptide for purification by immobilized metal ion affinity chromatography (Hochuli, E. et al, (1988) BiolTechnology 6:1321-1325).
- specific endoprotease cleavage sites can be introduced between the sequences of a fusion moiety and the peptide. It may be necessary to increase the solubility of a peptide by adding functional groups to the peptide, or by omitting hydrophobic regions of the peptide.
- DNA encoding a B7 molecule or portion thereof is linked in frame to DNA encoding an antigen to which an immune response is desired, e.g., a viral antigen or a tumor cell antigen.
- DNA encoding the amino acid sequence corresponding to an extracellular domain of a B7 antigen is joined to DNA encoding the amino acid sequences corresponding to the constant region of an immunoglobulin molecule (See e.g., US patent 5,580,756 or WO 97/28267).
- the second peptide can include an immunoglobulin constant region, for example, a human C ⁇ l domain or C ⁇ 4 domain or C ⁇ or portion thereof (e.g., the hinge, CH2 and CH3 regions of human IgC ⁇ l, or human IgC ⁇ 4, see e.g., Capon et al. US 5,116,964, incorporated herein by reference).
- a resulting B7Ig fusion protein may have altered solubility, binding affinity, stability and/or valency (i.e., the number of binding sites available per molecule) and may increase the efficiency of protein purification.
- the cysteine residues in the immunoglobulin constant region are conserved to allow for disulfide bonding and the formation of soluble dimeric B7Ig proteins.
- a portion of a B7 molecule is fused to the constant region of an IgM antibody or portion thereof, to allow the formation of soluble multimeric forms of B7Ig proteins.
- Particularly preferred B7Ig fusion proteins include an extracellular domain portion or variable region-like domain of human B7-1 or B7-2 coupled to an immunoglobulin constant region.
- the immunoglobulin constant region used in the soluble B7 molecule may contain genetic modifications which reduce or eliminate effector activity inherent in the immunoglobulin structure (see e.g., WO 97/28267).
- DNA encoding an extracellular portion of B7-1 or B7-2 can be joined to DNA encoding the hinge, CH2 and CH3 regions of human IgC ⁇ l and/or IgC ⁇ 4 modified by site directed mutagenesis.
- a non-human immunoglobulin constant region is used, preferably the constant region is humanized. Techniques for preparing chimeric or humanized antibodies are well known in the art (see e.g., Morrison et al., Proc. Natl. Acad. Sci. U.S.A.
- B7 fusion proteins and polypeptides produced by recombinant techniques may be secreted and isolated from a mixture of cells and medium containing the protein or peptide. Alternatively, the protein or peptide may be retained cytoplasmically and the cells harvested, lysed and the protein isolated.
- a cell culture typically includes host cells, media and other ingredients. Suitable media for cell culture are well known in the art. Protein and polypeptides can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins and peptides. Techniques for transfecting host cells and purifying proteins and peptides are described in further detail herein.
- B7 molecules for those which retain a characteristic B lymphocyte antigen activity as described herein can be accomplished using one or more of several different assays.
- the peptides can be screened to see that they maintain specific reactivity with an anti-B7 monoclonal antibody that binds to a naturally occurring B7 molecule.
- appropriate cells such as COS cells, can be transfected with a DNA encoding a polypeptide to be tested. Production of secreted forms of B7 can be evaluated using anti-B7 monoclonal antibody or CTLA4Ig or CD28 fusion protein in an immunoprecipitation assay.
- the ability of cells expressing a peptide of interest to bind to CTLA4 or CD28 on plates by panning can also be tested.
- the ability of a test peptide to compete with a naturally occurring B7 molecule for binding to CD28 or CTLA4 can also be tested.
- assays test the functional characteristics of the B7 antigen.
- the ability of T cells to synthesize cytokines depends not only on occupancy or cross-linking of the T cell receptor for antigen (the "primary activation signal” provided by, for example anti-CD3, or phorbol ester to produce an "activated T cell”), but also on the induction of a costimulatory signal, in this case, by interaction with a B lymphocyte antigen, e.g. B7-1 or B7-2 with CD28 and or CTLA4 molecules on the T cell.
- a B lymphocyte antigen e.g. B7-1 or B7-2 with CD28 and or CTLA4 molecules on the T cell.
- B7 molecules to their natural ligand(s) on T cells that have received signal one via the T cell receptor, has the effect of transmitting a signal to the T cell that induces the production of increased levels of cytokines, particularly of interleukin-2, which in turn stimulates the proliferation of the T lymphocytes.
- Other assays for B7 function thus, involve assaying for the synthesis of cytokines, such as interleukin-2, interleukin-4 or other cytokines, and/or assaying for T cell proliferation by CD28 + T cells which have received a primary activation signal.
- T cells can be provided with a first or primary activation signal by contacting them with anti-T3 monoclonal antibody (e.g. anti-CD3) or phorbol ester or. more preferably, by antigen in association with class I or class II MHC molecules.
- T cells which have received a primary activation signal are referred to herein as activated T cells.
- B7 function is assayed by adding a source of B7 (e.g., cells expressing a peptide having B7 activity or a secreted form of B7) and a primary activation signal such as antigen in association with class I or class II MHC to a T cell culture and assaying for a functional result, e.g., assaying the culture supernatant for interleukin-2, gamma interferon, or other known or unknown cytokine.
- a source of B7 e.g., cells expressing a peptide having B7 activity or a secreted form of B7
- a primary activation signal such as antigen in association with class I or class II MHC
- a functional result e.g., assaying the culture supernatant for interleukin-2, gamma interferon, or other known or unknown cytokine.
- any one of several conventional assays for interleukin-2 can be employed, such as the assay described in Proc
- T cell proliferation can also be measured as described in the Examples below.
- Peptides that retain the characteristics of the B7 antigen as described herein may result in increased per cell production of cytokines, such as IL-2, by T cells and may also result in enhanced T cell proliferation when compared to a negative control in which a costimulatory signal is lacking.
- compositions and/or agents described herein are administered to subjects in whom it is desirable to promote an immune response.
- soluble B7 molecules are administered with an antigen prophylactically, e.g., prior to infection with a pathogen or to a subject who is free of cancer.
- the subject soluble B7 molecules are administered therapeutically, e.g., to subjects who have a preexisting condition which would benefit from enhanced costimulation, e.g., a subject who has cancer or is infected with a pathogen.
- the subject costimulatory molecules are coadministered with an antigen preparation.
- an antigen can be a protein, a polysaccharide, a lipopolysaccharide, a lipopeptide, or it can be a combination of any of these.
- the antigen can include a native protein or protein fragment, of a synthetic protein or protein fragment, or peptide; it can include glycoprotein, glycopeptide, lipoprotein, lipopeptide, nucleoprotein, nucleopeptide; it can include a peptide-peptide conjugate; or it can include a recombinant nucleic acid expression product.
- an antigenic preparation comprises a mixture of antigens, e.g., the antigen is administered in the form of irradiated cells (e.g., tumor cells or virally infected cells), viral particles, or a crude homogenate.
- a purified preparation of an antigenic peptide or a recombinant form of an antigenic peptide is administered to the subject e.g., a viral peptide or a tumor associated antigen.
- an antigen preparation comprises an MHC class I restricted peptide.
- an antigen preparation comprises an MHC class II restricted peptide.
- an antigen preparation comprises a combination of a class I restricted peptide and a class II restricted peptide for administration to the subject.
- the antigen is administered by "genetic immunization.”
- a DNA expression vector encoding the peptide of interest is injected into the host animal, e.g., into the skin or into a muscle of the subject.
- the gene products are correctly synthesized and glycosylated, folded, and expressed by the subject.
- antigens which are difficult to obtain in sufficient quantity or purity can be administered.
- DNA is injected into muscles or delivered into the skin coated onto gold microparticles by a particle bombardment device, a "gene gun.” Genetic immunization has been shown to induce specific humoral responses and cellular immune responses (See, e.g., Mor et al. 1995. J. Immunol. 155:2039; Xu and Liew. 1995. Immunology. 84:173; Davis et al. 1994. Vaccine. 12:1503).
- soluble B7 molecules may vary depending upon the subject to be treated.
- soluble B7 molecules can be administered with an antigen and/or can be administered alone prior to administration of an antigen, or can be administered alone for several days after administering an antigen.
- soluble B7 molecules can be administered "genetically" by administering a nucleic acid molecule encoding a soluble B7 molecule or portion thereof.
- a soluble B7 molecule and an antigen are administered in the form of a conjugate. Dosage procedures of administration of soluble B7 molecules may be adjusted to provide the optimum therapeutic response for each subject without undue experimentation.
- antibody titers to an antigen or cellular immune responses e.g., DTH responses (Puccetti et al. 1994. Eur. J. Immunol. 24:1446)
- an antigen or cellular immune responses e.g., DTH responses (Puccetti et al. 1994. Eur. J. Immunol. 24:1446)
- an antigen can be measured to determine whether or not the subject is developing an immune response or is manifesting an enhanced immune response to the antigen and the dosage regimen can be adjusted accordingly.
- the active agent or composition may also be administered parenterally or intraperitoneally.
- the agent can be administered, for example, intranasally, orally, intravenously, intramuscularly, subcutaneously or mucosally.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols. and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
- compositions suitable for injection include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- a pharmaceutical composition of the invention can be formulated to be suitable for a particular route of administration.
- a pharmaceutical composition of the invention can be suitable for injection, inhalation or insufflation (either through the mouth or the nose), or for intranasal, mucosal, oral, buccal, parenteral, rectal, intramuscular, intravenous, intraperitoneal, and subcutaneous delivery.
- the agent or composition will be sterile. In addition, they shall be stable under the conditions of manufacture and storage and shall be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, asorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating active composition or agent in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filter sterilization.
- dispersions are prepared by incorporating the active compound (e.g., the costimulatory molecule and/or the antigen and any additional agent) into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient (e.g., agent or composition) plus any additional desired ingredient from a previously sterile- filtered solution thereof.
- agent or composition can be administered in a form suitable for use with a needleless injector device (such devices are known in the art (see, e.g., 5,383,851; 5,581,198; 5,846,233) for example as described in Mol Med 1998. 4:109.
- a needleless injector device such devices are known in the art (see, e.g., 5,383,851; 5,581,198; 5,846,233) for example as described in Mol Med 1998. 4:109.
- the protein may be orally administered, for example, with an inert diluent or an assimilable edible carrier.
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the therapeutic compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
- Dosage unit form refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active agent or composition for the treatment of individuals.
- pharmaceutically acceptable carrier includes, e.g., solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like.
- solvents e.g., solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Supplementary agents can also be incorporated.
- the agents of the invention are administered to subjects in a biologically compatible form suitable for pharmaceutical administration in vivo to enhance immune responses.
- biologically compatible form suitable for administration in vivo is meant a form of the protein to be administered in which any toxic effects are outweighed by the therapeutic effects of the agent.
- subject is intended to include living organisms in which an immune response can be elicited, e.g., mammals. Examples of subjects include humans, non-human primates, dogs, cats, mice, rats, and transgenic species thereof.
- Administration of a peptide having the activity of B7 molecule as described herein can be in any pharmacological form including a therapeutically active amount of soluble B7 peptide alone, soluble B7 peptide in combination with an antigen, and soluble B7 peptide in combination with a pharmaceutically acceptable carrier.
- Administration of a therapeutically or prophylactically active amount of the compositions of the present invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result.
- the administration of a soluble B7 molecule results in an enhanced immune response to an antigen (e.g., a viral or a tumor cell antigen).
- an antigen e.g., a viral or a tumor cell antigen
- a cellular and/or humoral immune response can be measured using art recognized techniques. Measurements of immune responses to an antigen can be made in vivo or assayed in vitro. For example, immune cell reactivity to a tumor cell can be measured by performing a biopsy and looking for cellular infiltrates. In situ cytokine staining can be performed at sites of infection or near the site of a tumor or in draining lymph nodes. In vitro culturing of cells can be performed to test for cellular reactivity to an antigen (e.g., proliferation and/or cytokine production in the presence of the antigen and/or cytotoxic activity against the antigen).
- an antigen e.g., proliferation and/or cytokine production in the presence of the antigen and/or cytotoxic activity against the antigen.
- a therapeutically or prophylactically active amount of a polypeptide having B7 activity may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the peptide to elicit a desired response in the individual. Dosage periods may be adjusted to provide the optimum therapeutic or prophylactic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
- the active compound may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active compound may be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound.
- the invention further pertains to the active compound in the form of a medicament for use in therapy as described herein.
- the active compound may also be used in the manufacture of a medicament for use in therapy.
- the subject treatment may be supplemented with the administration of additional agents to further augment the immune response.
- additional agents for example, adjuvants and/or cytokines can be administered to a subject.
- cytokines such as: granulocyte-macrophage colony stimulating factor, macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 1, interluekin 2, interleukin 3. interleukin 4, interleukin 5, interleukin 6, interleukin 7. interleukin 10, and/or interleukin 12 can be administered. Interferon, e.g., ⁇ , ⁇ , and/or gamma interferon can also be administered.
- cytokines such as IL-12 which favor the development of Thl-type T helper responses and the development of cellular immunity are administered.
- an additional agent that modulates a costimulatory signal e.g., an anti-CD28 antibody can be administered to the subject.
- agents which are known adjuvants can be administered.
- the only adjuvant widely used in humans has been alum (aluminum phosphate or aluminum hydroxide).
- Other adjuvants e.g., saponin and its purified component Quil A, Freund's complete adjuvant and other adjuvants used in research and veterinary applications have potential use in human vaccines.
- new chemically defined preparations such as muramyl dipeptide, monophosphoryl lipid A, phospholipid conjugates such as those described by Goodman- Snitkoff et al. J. Immunol.
- resorcinols non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether
- enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol can also be used.
- the antigen can e.g., be encapsulated within a proteoliposome as described by Miller et al., J. Exp. Med.
- lipid vesicles such as Novasome TM lipid vesicles (Micro Vescular Systems, Inc., Nashua, N. H.), to further enhance immune respones.
- Novasome TM lipid vesicles Micro Vescular Systems, Inc., Nashua, N. H.
- B7-1 and B7-2 are two potent co-stimulatory molecules on the surface of APCs.
- the effects of a soluble form of B7-2 on in vivo T cell responses have been examined.
- the soluble molecule is a chimeric protein containing the extracellular domain of B7-2 fused to the Fc region of mouse IgG2a.
- Administration of B7- 2Ig fusion protein at the time of immunization with class II restricted peptides significantly enhanced antigen-specific T cell proliferation and cytokine responses.
- B7- 2Ig administration also enhanced the CTL response to immunization with a class I-restricted peptide.
- mice Female BALB/cJ mice (Jackson Labs, Bar Harbor, ME) 7 to 10 weeks of age were used throughout this study.
- peptides used were H-2 d -restricted immunodominant epitopes from nucleoprotein (NP) of influenza virus A/PR18/34.
- NP nucleoprotein
- AIPR/8/34 influenza virus stock was prepared and titered by injection of seed virus at a dilution of 104 into 10 day embryonated chicken eggs. After 42 hr. of incubation, the allantoic fluids of infected eggs were individually harvested and sterility confirmed on blood agar plates. Sterile fluids were pooled, aliquots prepared and quick- frozen with storage at -70°C Plaque titration (Bucher, D. J. et al. 1991, JClin Microbiol 29:2484) was performed following quick-thawing and dilution of the virus (in allantoic fluid.)
- B7-2Ig fusion protein was expressed and purified as described previously (Fields, P. E., et al. 1998. J Immunol 161:5268).
- expression plasmid pED was constructed from cDNA encoding the signal and extracellular domains of murine B7-2 joined to the genomic DNA encoding the hinge, CH2, and CH3 regions of mouse IgG2a.
- the expression vector was transfected into a CHO cell line and amplified by previously described techniques (Kaufman, R. J., et al. 1988. Journal of Biological Chemistry 263:6352.). Concentrated cell culture supernatant was passed over a rProtein A Sepharose Fast Flow column (Pharmacia Biotech).
- B7-2Ig was eluted with 20mM citrate pH 3.0, neutralized with 1M Tris (Sigma) pH 8.0, and formulated in PBS pH 7.2 by buffer exchange. Protein concentration was calculated using an absorbance at 280nm and an extinction coefficient of 1.33 cm/mg/ml. Endotoxin levels were less than 0.25 EU/mg as determined by gel clot assay (Cape Cod Associates). The percentage of protein as multimer was less than 1% as determined by analysis using TSK 3000 SWXL column (Toso Haas USA, Mongomeryville, PA). In vitro co-stimulatory activity of B7- 2Ig has been demonstrated (Fields, P. E., et al. 1998.
- mice 100 ⁇ g of the indicated peptide or peptide mixture was mixed 1 :1 by volume with IFA (Sigma) and emulsified. Mice were immunized subcutaneously with antigen/IFA emulsion in 100 ⁇ l at the base of the tail. B7-2Ig in 100 ⁇ l was administered subcutaneously at a site proximal to the peptide immunization site. In experiments where lymph node cells were harvested, mice received peptide and B7-2Ig as described above both at the base of the tail and at the back of the neck. Treatment groups consisted of 5 mice each. B7-2Ig was administered in 0.1% aluminum hydroxide (Rehydragel, Rehies, Dublin, Ireland).
- Metafane (Mallinckrodt Veterinary, Mundelein, IL) was administered by nose cone until mice lost reflex response. Live virus diluted in PBS was administered intra-nasally in a final volume of 40 ⁇ l. The lethal virus dose (4,000 PFU/mouse) caused 100% mortality in non-immunized mice. Immunization dose of 40 PFU/mouse caused no morbidity and resulted in complete protection from lethal challenge.
- Lymph nodes excluding mesenteric nodes
- spleens were collected on the indicated days and single cell suspensions prepared and cultured in flat bottom 96 well plates at 5 x 10 5 cells/well in 200 ⁇ l in RPMI 1640 (Gibco/BRL), supplemented to contain 5 x 10 "5 M 2ME, 2mM Lglutamine, 100 U/ml Penicillin and lOO. ⁇ g/ml Streptomycin (Gibco/BRL), 10% FCS. Class II-restricted peptides were added at the start of culture at the indicated concentration.
- Proliferation was measured by 3H thymidine incorporation following an 18 hour pulse (l ⁇ C/well) with a 1450 Microbeta Plate Reader (Wallac). Comparison of proliferative responses from lymph node cells on days 3, 5, 7, and 9 post primary immunization were conducted. Secondary responses were assessed from spleens harvested three days after secondary immunization.
- samples of blood were collected by retro-orbital bleed from mice anesthetized with Aerrane, (Ohmeda Caribe, Inc, Guayama, PR). Samples were diluted with 100 ⁇ l PBS containing 50U heparin. A 40 ⁇ l sample was removed for white blood cell counts. Differential counts on samples were not routinely performed. The percentage of lymphocytes in the white blood cell fraction was 69% + 8% by differential count of 100 samples taken at various times during the study. Cells were washed to remove heparin.
- Cells were plated in 96 well round bottom Costar plates in lOO ⁇ l volume for a total of 8 x 10 3 while blood cells per well. A total of 80 wells were plated for each blood sample. Sixteen wells on each plate received only media with irradiated spleen cells. On day 7 of culture, supernatants were decanted by inverting the plates and cell pellets suspended by plate agitation. Antigen-positive (Ag-positive) targets were prepared by overnight pulse of P815 cells with 1 Oug/ml of the class I-restricted peptide.
- Experimental release - medium release X 100 total release - medium release where total release was the average cpm of all wells which received targets and triton-X-100, and medium release was the average cpm + SD of all wells which received targets and media only. Mean specific percent lysis per well was calculated according to the formula:
- mice were immunized with peptides in the presence or absence of B7-2Ig administration.
- the class II-restricted peptides aa 55-77 and aa 206-229 from NP of A/PR/8/34 influenza virus were delivered subcutaneously as a mixture in IFA. These peptides have been shown to be immunodominant CD4+ Th cell epitopes (Brett, S. J., et al. 1991. Journal Immunology 147:1647, Brett, S. J., and J. P. Tite. 1996).
- B7-2Ig in 0.1% alum was administered at a proximal site.
- peptide-specific proliferative responses were measured from lymph node cells on days 3, 5, 7 and 9 post immunization. The kinetics of the response were not affected by administration of B7- 2Ig.
- Optimal proliferative responses were observed from both B7-2Ig and control treated mice at day 7 and 9 post immunization.
- Peptide immunized mice which did not receive B7-2Ig received alum as a control. Proliferation was assessed by 3 H-thymidine incorporation. Data are expressed as the average cpm/well of 5 mice per group ⁇ SD. Similar results were obtained when mouse IgG2a mAb was used as a control. Data are from one of three representative experiments.
- mice were immunized with peptides in the presence or absence of B7-2Ig treatment, and boosted forty-six days later without further B7-2Ig administration. Spleen cells were collected 3 days after the second immunization and the peptide-specific proliferative response was measured.
- Five mice per group were immunized with peptides alone (-0 -), treated with B7-2Ig alone (- ⁇ -), or immunized with peptides and treated with B7-2Ig (-"-).
- both groups of peptide immunized mice were re-immunized with peptides in the absence of B7-2Ig coadministration.
- Non-immunized mice received IFA only. Three days after re-immunization, spleen cells were restimulated in vitro with the indicated concentration of each of the two peptides used for immunization. Proliferation was assessed by 3 H-thymidine incorporation. Data are expressed as the average cpm/well of 5 mice per group ⁇ SD. Data are from one of two replicate experiments. These data indicate that B7- 2Ig, when used as an adjuvant for a primary T cell response, enhances the recall response.
- B7-2Ig as immune adjuvant differentially promoted development of Thl or Th2 responses
- peptide-specific cytokine responses following primary immunization were analyzed from lymph node cells of immunized mice at 3,5,7 and 9 days post immunization. Just as with proliferative responses, optimal cytokine responses were observed at day 9.
- Antigen specific cytokine production was not observed in cultures from unimmunized mice treated with B7-2Ig.
- B7-2Ig Enhances CTL Response To Class I-Restricted Peptide. Interaction of membrane bound B7 with CD28 has been shown to allow induction of in vitro CTL responses in the absence of CD4+ cells (Harding, F. A. et al. 1993, J Exp Med 177:1791).
- mice were immunized with the immunodominant class I-restricted peptide in IFA with or without concomitant B7-2Ig administration.
- Peptide specific CTL responses were measured from unfractionated peripheral blood cells using the small blood sample, CTL assay as described in Materials and Methods. This assay makes possible the analysis of large numbers of mice within a single experiment, assessment of the statistical significance of differences between groups, repeated CTL assays from individual mice during the course of an immune response, and investigation of correlation between CTL responses and in vivo results.
- mice were immunized with an IFA emulsion containing either the class I-restricted peptide alone or a mixture of the class I-restricted peptide and the two class Il-restricted peptides described for Figures 1 and 2 and Table 1 above.
- CTL responses were measured from unfractionated peripheral blood cells ( Figure 4).
- Peptide immunization was done as a single emulsion in IFA. Mice were immunized and treated as indicated. Three weeks later, CTL responses were measured from peripheral blood. Data are expressed as mean specific lysis + SD. The value for the live virus immunized group is from a single pool of 2 mice, and the average mean specific lysis of this group was 52 ⁇ 12 obtained from 18 mice tested in 9 experiments.
- mice There were five mice per group in all other groups. Mean specific lysis of the group which received Class Il-restricted peptides in IFA and control Ig in alum has been subtracted from groups shown which received control Ig. Mean specific lysis of the group which received class Il-restricted peptides in IFA and B7-2Ig in alum has been subtracted from groups shown which received B7-2Ig. The data shown are from one of four replicate experiments.
- mice immunized with peripheral blood cells peaked at 2 to 3 weeks and waned in the fifth week in both mice immunized with live virus and mice immunized with peptides and treated with B7-2Ig, again indicating similarity of the responses. As discussed below, however, mice immunized with the peptide mixture and treated with B7-2Ig were not protected from lethal virus challenge.
- Optimal antigen-specific activation and regulation of T cells requires the delivery of a costimulatory signal from B7 molecules on the surface of the APC to CD28 and CTLA-4 on the surface of the T cell (Boussiotis, V. A., et al. 1996, Immunol Rev 153:5; Lenschow, D. J. et al. 1996, Annual Review Immunology 14:233; Green, J. M. et al. 1994. Immunity 1:501; Tivol, E. A. et al. 1995, Immunity 3:541 and Waterhouse, P., 1995, Science 270:985). Work in a wide variety of mouse models has shown that immune responses can be enhanced by increased cell surface expression of B7.
- B7-2Ig a soluble protein form of B7-2, B7-2Ig has been developed, consisting of the Fc of mouse IgG2a fused with an extracellular portion of B7-2 attached to each Ig chain.
- B7-2Ig enhances antigen specific Th cell and CTL responses.
- B7-2Ig presents a simple alternative to ex vivo B7 transduction of tumor cells or the use of viral or D ⁇ A vectors for optimizing B7-2 mediated costimulation.
- Th2 differentiation is more dependent on B7 costimulation than is Thl differentiation (Lenschow, D. J. et al. 1995, J Exp Med 181:1145; Corry, D. B., et al. 1994, J Immunol 153:4142; Freeman, G. J. et al. 1995, Immunity 2:523 and Rulifson, I. C, A. et al. 1997, J Immunol 158:658).
- Anti-B7 mAb have been successfully used to manipulate T cell differentiation in vivo.
- Blockade of B7-1 with mAb has been reported to favor Th2 differentiation, whereas blockade of B 7-2 favors Thl differentiation (Kuchroo, V. K. et al. 1995, Cell 80: Mar 10(5):; Lenschow, D. J. et al. 1995, J Exp Med 181:1145; Corry, D. B. et al. 1994, J Immunol 153:4142; Freeman, G. J. et al. 1995, Immunity 2:523and Rulifson, I. C. et al. 1997, J Immunol 158:658).
- APC from B7 knockout mice
- B7-1 nor B7-2 appear to selectively regulate Thl or Th2 differentiation in vitro (Schweitzer, A. N. et al. 1997, J Immunol 2 158: 713).
- the data in this example show that in vivo administration of B7-2Ig enhances antigen specific cytokine responses of both the Thl and Th2 type. Therefore the therapeutic potential B7-2Ig is likely to be greatest in situations where elevation, not skewing, of the response is the goal.
- mice were capable of a much greater anti peptide response than that which is elicited by class I-restricted peptide immunization and B7-2Ig coadministration.
- mice immunized with class I and class Il-restricted peptides were less than that of mice immunized with live virus.
- Addition of B7-2Ig to the protocol increased the CTL response of mice immunized with the mixture of peptides to the level of mice immunized with live virus. Responses of these two groups were comparable, but the former group was not protected from lethal virus challenge. This result is consistent with those of Lawson et al. (Lawson, C. M. et al.
- formulation in alum results in greater enhancement than formulation in PBS.
- Administration of control Ig in alum does not affect responses, indicating that alum alone does not enhance the response.
- B7-2Ig Dependent Enhancement of Th Cytokine Responses 3
- mice per group were immunized at two subcutaneous sites with an IFA emulsion containing either lOO ⁇ g per injection of each of the two class Il-restricted peptides or PBS.
- lOO ⁇ g of B7-2IgG2a in 0.1 % alum or 0.1% alum alone was administered at sites proximal to the immunization sites.
- lymph node cells were harvested and restimulated in culture for three days with 5 ⁇ g/ml of each peptide. Values for each mouse were obtained by averaging results from triplicate wells. Data are expressed as the average concentration of cytokine of mice within a group ⁇ SD. Results are similar to those obtained when a control mouse IgG2a mAb was used as control. Data shown are from one of three replicate experiments. b Below the limits of detection of assay.
- Fusion proteins between an extracellular region of either B7-1 or B7-2 and IgG.2a have been evaluated for their ability to enhance anti-tumor responses in four different murine tumor models, including the poorly immunogenic melanoma B16/F10.
- a single vaccination with irradiated tumor cells when mixed with B7-1 or B7-2-IgG protected mice against a live tumor challenge. More significantly, 7-day established tumors regressed after vaccination with irradiated tumor cells mixed with B7-IgG. Even therapeutic administration of B7-IgG alone achieved similar decreases in tumor burden. Animals that had rejected an established tumor were resistant to a rechallenge, strongly suggesting that the anti-tumor effect of B7-IgG is mediated by tumor-specific immune mechanisms.
- B7-IgG exhibits potent adjuvant activity in combination with exogenously delivered and endogenous antigens.
- the expression plasmids for the murine B7-l-IgGIgG and B7-2-IgG2a fusion proteins were constructed by joining the DNA encoding the signal and extracellular domains of murine B7-1 or B7-2 to the DNA encoding the hinge-CH2-CH3 domains derived from a murine IgG2a antibody.
- the cysteine residues within the antibody hinge region remained conserved such that the mB7- 1 -IgGIgG2a or mB7-2- IgG2a produced is dimeric and bivalent. Fusion proteins were generated in which the IgG2a region is mutated in order to prevent binding by high affinity Fc receptors and complement activation (designated B7-IgG2mut).
- the following amino acid residues in the CH2 domain were replaced by alanine: leucine at position #235, glutamic acid at #318, lysine at #320, and lysine at #322.
- leucine at position #235 leucine at position #235
- glutamic acid at #318 glutamic acid at #318
- lysine at #320 lysine at #320
- lysine at #322 lysine at #322.
- P815 is a mastocytoma derived tumor cell line that grows as a solid tumor after intradermal (i.d.) injection of 5x 10 ⁇ cells into DBA/2 mice (Jackson Laboratories). The clone used in these experiments metastasizes spontaneously after i.d. injection and leads to the death of the mice after 25-35 days.
- MethA a tumor cell line derived from a sarcoma in Balb/C mice, grows as solid tumor after i.d. injection of 5x10 ⁇ cells (Balb/C mice from Taconic).
- B16/F10 a non-immunogenic tumor line derived from a melanoma in C57BL/6 mice (Taconic), grows as a solid tumor after i.d. injection of lx 10 ⁇ cells and causes death due to metastases after 25-35 days.
- the bladder carcinoma MB49 is also derived from C57BL/6 mice and lxl 0 ⁇ cells were injected i.d. to establish solid tumors after 5-7 days in 100% of mice.
- In vitro costimulation assay 2 x ⁇ naive murine splenocytes were plated in triplicate in 96-well plates coated with low concentrations of anti-CD3 mAb (0-500ng-ml of -2C11, Pharmingen). To provide the necessary signals for costimulation, the plates were either co-coated with anti-CD28 mAb (0-1 ⁇ g/ml) as positive control or with B7-l-IgG or B7- 2-IgG (0-9 ⁇ g/ml). B7-IgG was also added in soluble form or cross-linked by a secondary anti-mouse IgG2a Ab. The splenocytes were stimulated for 72 hours.
- IFN- ⁇ analysis was performed in a standard ELISA with the capture Ab R46A4 and biotinylated XGM1.2 as detection Ab.
- mice were vaccinated on day 0 at the same time that they were challenged with tumor cells.
- Mice were immunized with irradiated tumor cells (lx 10 7 cells) in PBS, mixed with 75-100 ⁇ g of mB7-l-IgG, B7-2- IgG, murine IgG, or nothing.
- the injection was given intra-footpad (i.fp.) in both hindlegs.
- Injection of B7-IgG was repeated once on day 3 or 5.
- animals were challenged with a defined dose of live tumor cells by i.d. injection of 50 ⁇ l in the right flank. Growth of the primary tumor and survival of animals was monitored over 40-60 days.
- a primary tumor was established by i.d. inoculation with a defined number of tumor cells. On day 5-7 (when tumors were clearly palpable), mice were vaccinated i.fp. with lxl 0 7 irradiated tumor cells mixed with lOO ⁇ g of B7-l-IgG, B7-2-IgG, or nothing. lOO ⁇ g B7-IgG was again injected i.fp. three days later. This vaccination regimen was repeated for two or three weeks. Growth of primary tumor and survival of mice was monitored from day 7 to day 40-70. In therapy models, tumor-bearing mice B7-IgG were treated with fusion protein alone. 50-100 ⁇ g of B7-l-IgG or B7-2-IgG alone was injected i.fp. twice a week for three weeks. Tumor growth and survival was monitored for 40 days.
- Spleens were collected from DBA/2 mice 10-14 days after a single immunization with irradiated P815 cells mixed with or without B7-l-IgG or B7-2IgG. After lysis of erythrocytes 20x 10° " splenocytes were restimulated in T25 flasks with 0.1 ng/ml PI A peptide and 5 U/ml IL-2 (Pharmingen) for 6 days. Then, a standard 5h Cr ⁇ l- release assay was performed with A20 cells as targets pulsed with lO ⁇ g/ml of PI A peptide or unpulsed with peptide. The percent of PlA-peptide specific lysis is expressed as the difference between the percent lysis of peptide-pulsed targets and the percent lysis of unpulsed targets.
- Immobilized or cross-linked B7-IgG provides costimulatory signal for suboptimally stimulated murine splenocytes in vitro.
- B7-l-IgG and B7-2- IgG fusion proteins bind to murine CD28 and CTLA-4.
- murine splenocytes were stimulated in vitro by culturing with plate-bound anti-CD3 mAb in combination with B7-IgG immobilized on the plates. Costimulation with plate-bound anti-CD28 mAb served as a positive control.
- B7-l-IgG and B7-2-IgG similarly induced a dose dependent increase in proliferation and IFN- ⁇ secretion (Figure 5).
- na ' ⁇ ve splenocytes were stimulated in triplicate for 72 h with 50 ng/ml anti-CD3 monoclonal antibody and increasing amounts of immobilized anti-CD28 antibody, or B7-1 or B7-2 IgG.
- the proliferative response was measured by incorporation of 3H-thymidine after a 6h pulse.
- Panels B and C show the amount of IFN ⁇ or IL2 respectively, released after 72h stimulation with 50ng/ml anti-CD3 antibody and indicated amounts of immobilized B7-2-IgG. Cytokines were measured by standard ELISA. In the absence of anti-CD3 stimulation, B7-IgG did not induce proliferation.
- B7-IgG proteins mutated in their Fc binding region were as effective in co-stimulating splenocytes when immobilized on the plate.
- Both B7-l-IgG or B7-2-IgG enhance the protective efficacy of an irradiated tumor cell vaccine
- the B7-IgG fusion proteins were evaluated as adjuvants in a prophylactic tumor vaccine model. Inoculation of 5x10 ⁇ live P815 tumor cells generates a solid tumor after 5-7 days in 100% of naive DBA/2 mice. 10 DBA/2 mice per group were immunized i.fp. once with 1 x 10 ⁇ irradiated P815 tumor cells. The cell vaccine was given alone or mixed with either lOO ⁇ g of B7-l-IgG, B7-2-IgG, or B7-l-IgG, B7-2-IgG mutated protein. B7-IgG was administered again on day 5.
- mice were immunized with irradiated P815 tumor cells mixed with the mutated fusion proteins, B7-IgGmut, that do not bind Fc-receptors and do not activate complement.
- the mutated molecules were less effective than wild type (Fig. 6, Table 2), suggesting a role for Fc binding of the B7-IgG molecules.
- mice were injected i.d. with P815 tumor cells at a dose that generated a palpable solid tumor after five to seven days.
- Solid P815 tumors were established on day 0 by i.d. injection of 5 x 10 ⁇ P815 cells.
- Vaccination started on day 7 after palpable tumors had developed.
- Figure 7 shows the results of mice injected i.fp. with either PBS as control (A, E), or with irradiated P815 tumor cells alone (B) or mixed with irrelevant mouse IgG2a Ab (F), or with irradiated P815 cells mixed with B7-1 (C)- or B7-2-IgG (G).
- the immunization was repeated on days 7, 14, 21.
- PBS, irrelevant Ab, or B7-IgG, respectively was administered again three days later. Tumor growth was monitored for 40 days. After 25-30 days animals in the control groups stared to die from spontaneous metastases. Panels D and H show the survival times of the different treatment groups. Data are representative for four independent experiments. The kinetics of tumor growth and survival after vaccination are shown in Figure 7, representative for four independent experiments. Beginning about one week after the first immunization, reduced tumor growth in the tumor regression in the groups of mice immunized with tumor cells mixed with B7-IgG was observed. Tumor growth was not reduced in groups treated with irradiated tumor cells alone or mixed with an irrelevant mouse IgG2a Ab.
- mice After three cycles of immunization with irradiated P815 tumor cells mixed with B7-IgG, the primary tumor had disappeared in 60-80% of mice. Regression of the primary tumor correlated with long-term survival of the mice. Immunization with irradiated P815 cells mixed with either B7-l-IgG or B7-2-IgG increased long-term survival to approximately 80% (Fig. 7, D, H). The majority of the mice in the untreated or irradiated tumor vaccine control groups generally died between 25 and 35 days, apparently due to spontaneous metastases formed in liver, spleen, and lymph nodes.
- Balb/c mice bearing 7-day old established MethA sarcomas were immunized with PBS, irradiated MethA cells alone, or irradiated MethA cells mixed with either B7-l-IgG or B7-2-IgG.
- Solid MethA or B16/F10 tumors were established in Balb/c or C57BL/6 mice, respectively.
- Figure 8 shows that ten mice per group were immunized i.fp. with either irradiated tumor cells alone (B, E), or mixed with 25 ⁇ g (C, D) or lOO ⁇ g (F, G) B7-l-IgG or B7-2-IgG, respectively.
- One group was treated with PBS alone (A, not shown for B16/F10). Tumor growth was monitored for 35 days. Mice with MethA tumors were euthanized once the tumor reached a size of 300mm2. Mice with the B16/F10 tumor were either euthanized once the tumor reached a size of 400mm2, or the animals died from a spontaneous metastases. The percent of surviving animals is shown in panel H. Experiments were repeated at least three times.
- mice with B7- IgGs in the absence of irradiated tumor cells did not protect mice against a tumor challenge.
- treatment of tumor-bearing mice with B7-l-IgG or B7-2-IgG alone reduced tumor growth and increased survival (Fig. 9).
- mice were either treated with PBS (D), irradiated tumor cells alone (0), irradiated tumor cells mixed with B7-l-IgG (A), or B7-2-IgG (O), or with B7-l-IgG (*) or B7-2-IgG alone (+).
- the mean value of tumor size for groups of 7-10 mice has been plotted. Mice were euthanized once their tumor reached a size of 400mm2 or were assigned this value if they died from metastatic disease. In all models tested, therapeutic treatment of tumor- bearing mice with B7-IgG alone slowed tumor growth, induced tumor regression and increased survival.
- data from the B16/F10 tumor model suggest that vaccination with irradiated tumor cells plus B7-IgG is a stronger anti-tumor treatment than therapy with B7-IgG alone, at least for poorly immunogenic tumors.
- B7-IgG mediated tumor cure is CD8 T cell dependent but IFN- ⁇ independent
- B7-IgG in SCID mice that lack mature T and B cells was evaluated. Solid tumors were established in SCID mice and then they were treated with either B7-IgG alone or with an irradiated cell vaccine plus B7-IgG. Neither treatment had an effect on tumor growth, demonstrating the dependence of B7-IgG mediated tumor responses on T or B cells ( Figure 10). Tumor-bearing mice were also treated after depleting CD8 or CD4 T cells. Depletion of CD8 or CD4 T cells by antibody injection was started one day prior to initiation of B7-IgG therapy. Successful depletion was verified by FACS analysis of PBL on day 28.
- B7-IgG in anti-tumor therapy or as vaccine adjuvant is more potent than a blocking antibody to CTLA4.
- B7-IgG treatment cured tumors or protected against tumor challenge where an anti-CTLA4 antibody had no effect despite its much higher affinity to CTLA4 and previous reports of its blocking activity.
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002373256A CA2373256A1 (en) | 1999-05-06 | 2000-05-05 | Use of soluble costimulatory molecules to enhance immune responses |
PL36091500A PL360915A1 (en) | 1999-05-06 | 2000-05-05 | Use of soluble costimulatory molecules to enhance immune responses |
JP2000616813A JP2002544170A (en) | 1999-05-06 | 2000-05-05 | Use of soluble costimulatory molecules to enhance immune response |
KR1020017014170A KR20020001865A (en) | 1999-05-06 | 2000-05-05 | Use of soluble costimulatory molecules to enhance immune responses |
EP00930437A EP1181053A2 (en) | 1999-05-06 | 2000-05-05 | Use of soluble costimulatory molecules to enhance immune responses |
AU48257/00A AU4825700A (en) | 1999-05-06 | 2000-05-05 | Use of soluble costimulatory molecules to enhance immune responses |
IL14610600A IL146106A0 (en) | 1999-05-06 | 2000-05-05 | Use of soluble costimulatory molecules to enhance immune responses |
BR0010711-5A BR0010711A (en) | 1999-05-06 | 2000-05-05 | Use of soluble co-stimulatory molecules to enhance immune responses |
NO20015396A NO20015396L (en) | 1999-05-06 | 2001-11-05 | Use of soluble costimulatory molecules to enhance immune responses |
HK02102335.8A HK1041810A1 (en) | 1999-05-06 | 2002-03-26 | Use of soluble costimulatory molecules to enhance immune responses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13294499P | 1999-05-06 | 1999-05-06 | |
US60/132,944 | 1999-05-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000067788A2 true WO2000067788A2 (en) | 2000-11-16 |
WO2000067788A3 WO2000067788A3 (en) | 2001-04-05 |
Family
ID=22456295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/012435 WO2000067788A2 (en) | 1999-05-06 | 2000-05-05 | Use of soluble costimulatory molecules to enhance immune responses |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1181053A2 (en) |
JP (1) | JP2002544170A (en) |
KR (1) | KR20020001865A (en) |
CN (1) | CN1377279A (en) |
AU (1) | AU4825700A (en) |
BR (1) | BR0010711A (en) |
CA (1) | CA2373256A1 (en) |
CZ (1) | CZ20013964A3 (en) |
HK (1) | HK1041810A1 (en) |
HU (1) | HUP0201222A3 (en) |
IL (1) | IL146106A0 (en) |
NO (1) | NO20015396L (en) |
PL (1) | PL360915A1 (en) |
WO (1) | WO2000067788A2 (en) |
ZA (1) | ZA200109376B (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6803039B2 (en) | 2000-05-18 | 2004-10-12 | Japan Tobacco Inc. | Human monoclonal antibody against a costimulatory signal transduction molecule AILIM |
US7030225B1 (en) | 1997-02-27 | 2006-04-18 | Japan Tobacco, Inc. | Antibodies to JTT-1 protein, cells secreting such antibodies, and methods of making such antibodies |
US7045615B2 (en) | 1997-02-27 | 2006-05-16 | Japan Tobacco, Inc. | Nucleic acids encoding JTT-1 protein |
WO2007067681A2 (en) * | 2005-12-08 | 2007-06-14 | University Of Louisville Research Foundation, Inc. | Immunostimulatory compositions and methods |
US7438905B2 (en) | 2001-03-01 | 2008-10-21 | Japan Tobacco, Inc. | Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM |
US7465445B2 (en) | 1999-08-30 | 2008-12-16 | Japan Tobacco Inc. | Methods of preventing or treating graft versus host reaction by administering an antibody or portion thereof that binds to AILIM |
US7465444B2 (en) | 2001-03-27 | 2008-12-16 | Japan Tobacco, Inc. | Methods of suppressing or treating an inflammatory bowel disease by administering an antibody or portion thereof that binds to AILIM |
US7745215B2 (en) | 2005-12-08 | 2010-06-29 | University Of Louisville Research Foundation, Inc. | Methods and compositions for expanding T regulatory cells |
US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
US10080808B2 (en) | 2012-10-11 | 2018-09-25 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
US10124045B2 (en) | 2013-11-04 | 2018-11-13 | Uti Limited Partnership | Methods and compositions for sustained immunotherapy |
US10485882B2 (en) | 2015-05-06 | 2019-11-26 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101213199B (en) * | 2005-06-30 | 2013-12-18 | 卫材R&D管理有限公司 | Compounds for preparing immunological adjuvant |
EA201490381A1 (en) * | 2011-07-29 | 2014-06-30 | Селекта Байосайенсиз, Инк. | SYNTHETIC NANOSEAGES WHICH STIMULATE THE FORMATION OF HUMORAL IMMUNE RESPONSE AND IMMUNE RESPONSE MEDIATED BY CYTOTOXIC T-LYMPHOCYTES (CTL) |
CA2867516A1 (en) * | 2012-04-02 | 2013-10-10 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium for induction of cellular immune response |
CN110743006B (en) * | 2019-11-22 | 2020-08-25 | 北京启辰生生物科技有限公司 | Composition for synergistically relieving immune cell failure and application |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000006605A2 (en) * | 1998-07-28 | 2000-02-10 | Micromet Ag | Heterominibodies |
-
2000
- 2000-05-05 WO PCT/US2000/012435 patent/WO2000067788A2/en not_active Application Discontinuation
- 2000-05-05 AU AU48257/00A patent/AU4825700A/en not_active Abandoned
- 2000-05-05 JP JP2000616813A patent/JP2002544170A/en not_active Withdrawn
- 2000-05-05 IL IL14610600A patent/IL146106A0/en unknown
- 2000-05-05 PL PL36091500A patent/PL360915A1/en not_active Application Discontinuation
- 2000-05-05 CN CN00810038A patent/CN1377279A/en active Pending
- 2000-05-05 HU HU0201222A patent/HUP0201222A3/en unknown
- 2000-05-05 BR BR0010711-5A patent/BR0010711A/en not_active Application Discontinuation
- 2000-05-05 CZ CZ20013964A patent/CZ20013964A3/en unknown
- 2000-05-05 EP EP00930437A patent/EP1181053A2/en not_active Withdrawn
- 2000-05-05 CA CA002373256A patent/CA2373256A1/en not_active Abandoned
- 2000-05-05 KR KR1020017014170A patent/KR20020001865A/en not_active Application Discontinuation
-
2001
- 2001-11-05 NO NO20015396A patent/NO20015396L/en not_active Application Discontinuation
- 2001-11-14 ZA ZA200109376A patent/ZA200109376B/en unknown
-
2002
- 2002-03-26 HK HK02102335.8A patent/HK1041810A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000006605A2 (en) * | 1998-07-28 | 2000-02-10 | Micromet Ag | Heterominibodies |
Non-Patent Citations (4)
Title |
---|
CHEN AOSHUANG ET AL: "Non-glycosylated human B7-1(CD80) retains the capacity to bind its counter-receptors." FEBS LETTERS, vol. 428, no. 3, 29 May 1998 (1998-05-29), pages 127-134, XP002154489 ISSN: 0014-5793 * |
MORO MONICA ET AL: "Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules." CANCER RESEARCH, vol. 59, no. 11, 1 June 1999 (1999-06-01), pages 2650-2656, XP002154490 ISSN: 0008-5472 * |
RAO JAY B ET AL: "IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: Enhancement by simultaneous B7-1 expression." JOURNAL OF IMMUNOLOGY, vol. 156, no. 9, 1996, pages 3357-3365, XP002154488 ISSN: 0022-1767 * |
RENNERT PAUL ET AL: "The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion." INTERNATIONAL IMMUNOLOGY, vol. 9, no. 6, 1997, pages 805-813, XP000971089 ISSN: 0953-8178 * |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7247612B2 (en) | 1997-02-27 | 2007-07-24 | Japan Tobacco Inc. | Methods of treating an inflammatory disease with a JJT-1 polypeptide |
US7294473B2 (en) | 1997-02-27 | 2007-11-13 | Japan Tobacco Inc. | Methods of identifying substances that interact with JTT-1 protein |
US7045615B2 (en) | 1997-02-27 | 2006-05-16 | Japan Tobacco, Inc. | Nucleic acids encoding JTT-1 protein |
US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
US8389690B2 (en) | 1997-02-27 | 2013-03-05 | Japan Tobacco Inc. | Antibodies to JTT-1 protein and cells secreting such antibodies |
US7196175B2 (en) | 1997-02-27 | 2007-03-27 | Japan Tobacco Inc. | Antibodies to JTT-1 protein and cells secreting such antibodies |
US7217792B2 (en) | 1997-02-27 | 2007-05-15 | Japan Tobacco Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
US7932358B2 (en) | 1997-02-27 | 2011-04-26 | Japan Tobacco Inc. | Antibodies to JTT-1 protein and cells secreting such antibodies |
US7030225B1 (en) | 1997-02-27 | 2006-04-18 | Japan Tobacco, Inc. | Antibodies to JTT-1 protein, cells secreting such antibodies, and methods of making such antibodies |
US7279560B2 (en) | 1997-02-27 | 2007-10-09 | Japan Tobacco Inc. | Antibody fragments to JTT-1 protein and cells secreting such antibody fragments |
US7226909B2 (en) | 1997-02-27 | 2007-06-05 | Japan Tobacco Inc. | Methods of inhibiting transmission of a costimulatory signal of lymphocytes |
US7259147B2 (en) | 1997-02-27 | 2007-08-21 | Japan Tobacco Inc. | Methods of treating multiple sclerosis with a JTT-1 polypeptide |
US7465445B2 (en) | 1999-08-30 | 2008-12-16 | Japan Tobacco Inc. | Methods of preventing or treating graft versus host reaction by administering an antibody or portion thereof that binds to AILIM |
US7998478B2 (en) | 1999-08-30 | 2011-08-16 | Japan Tobacco, Inc. | Pharmaceutical composition for treating immune diseases |
US7988965B2 (en) | 2000-05-18 | 2011-08-02 | Japan Tobacco, Inc. | Methods of treating systemic lupus erythematosus with an antibody against costimulatory signal transduction molecule ailim |
US6803039B2 (en) | 2000-05-18 | 2004-10-12 | Japan Tobacco Inc. | Human monoclonal antibody against a costimulatory signal transduction molecule AILIM |
US7166283B2 (en) | 2000-05-18 | 2007-01-23 | Japan Tobacco Inc. | Methods of treating an inflammatory disorder and prohibiting proliferation, cytokine production, and signal transduction with antibody against costimulatory signal transduction molecule AILIM |
US7438905B2 (en) | 2001-03-01 | 2008-10-21 | Japan Tobacco, Inc. | Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM |
US8052972B2 (en) | 2001-03-27 | 2011-11-08 | Japan Tobacco, Inc. | Remedies for inflammatory bowel diseases |
US7465444B2 (en) | 2001-03-27 | 2008-12-16 | Japan Tobacco, Inc. | Methods of suppressing or treating an inflammatory bowel disease by administering an antibody or portion thereof that binds to AILIM |
WO2007067682A2 (en) * | 2005-12-08 | 2007-06-14 | University Of Louisville Research Foundation, Inc. | In vivo cell surface engineering |
US7598345B2 (en) | 2005-12-08 | 2009-10-06 | University Of Louisville Research Foundation, Inc. | Immunostimulatory compositions and methods |
WO2007067681A3 (en) * | 2005-12-08 | 2008-01-03 | Univ Louisville Res Found | Immunostimulatory compositions and methods |
US8017582B2 (en) | 2005-12-08 | 2011-09-13 | University Of Louisville Research Foundation, Inc. | Immunostimulatory compositions and methods |
WO2007067682A3 (en) * | 2005-12-08 | 2007-11-15 | Univ Louisville Res Found | In vivo cell surface engineering |
WO2007067681A2 (en) * | 2005-12-08 | 2007-06-14 | University Of Louisville Research Foundation, Inc. | Immunostimulatory compositions and methods |
US9079976B2 (en) | 2005-12-08 | 2015-07-14 | University Of Louisville Research Foundation, Inc. | Immunostimulatory compositions and methods |
US7745215B2 (en) | 2005-12-08 | 2010-06-29 | University Of Louisville Research Foundation, Inc. | Methods and compositions for expanding T regulatory cells |
US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
US11000596B2 (en) | 2010-11-12 | 2021-05-11 | UTI Limited Parttiership | Compositions and methods for the prevention and treatment of cancer |
US10172955B2 (en) | 2010-11-12 | 2019-01-08 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
US10080808B2 (en) | 2012-10-11 | 2018-09-25 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
US10905773B2 (en) | 2012-10-11 | 2021-02-02 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
US10124045B2 (en) | 2013-11-04 | 2018-11-13 | Uti Limited Partnership | Methods and compositions for sustained immunotherapy |
US11338024B2 (en) | 2013-11-04 | 2022-05-24 | Uti Limited Partnership | Methods and compositions for sustained immunotherapy |
US10485882B2 (en) | 2015-05-06 | 2019-11-26 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
Also Published As
Publication number | Publication date |
---|---|
NO20015396L (en) | 2002-01-02 |
HUP0201222A2 (en) | 2002-08-28 |
WO2000067788A3 (en) | 2001-04-05 |
CZ20013964A3 (en) | 2002-06-12 |
ZA200109376B (en) | 2003-03-13 |
JP2002544170A (en) | 2002-12-24 |
KR20020001865A (en) | 2002-01-09 |
CN1377279A (en) | 2002-10-30 |
EP1181053A2 (en) | 2002-02-27 |
CA2373256A1 (en) | 2000-11-16 |
HK1041810A1 (en) | 2002-07-26 |
HUP0201222A3 (en) | 2004-07-28 |
BR0010711A (en) | 2002-02-13 |
IL146106A0 (en) | 2002-07-25 |
AU4825700A (en) | 2000-11-21 |
PL360915A1 (en) | 2004-09-20 |
NO20015396D0 (en) | 2001-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Corr et al. | Costimulation provided by DNA immunization enhances antitumor immunity. | |
KR100689739B1 (en) | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens | |
AU765822B2 (en) | CD40 binding molecules and CTL peptides for treating tumors | |
CA2480162C (en) | Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40 | |
EP1181053A2 (en) | Use of soluble costimulatory molecules to enhance immune responses | |
EP1086224B1 (en) | B2 microglobulin fusion proteins and high affinity variants | |
SK3062001A3 (en) | Method for down-regulating osteoprotegerin ligand activity | |
US20210283242A1 (en) | Immune-mediated coronavirus treatments | |
TW514530B (en) | Tumor vaccines and methods for their production | |
KR20200142600A (en) | Combinations of modalities for the treatment of diabetes | |
Facciabene et al. | Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects | |
KR20070068398A (en) | Combination of a recombinant mycobacterium and a biologically active agent as a vaccine | |
US7011833B1 (en) | Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent | |
US20040091492A1 (en) | Beta2 microglobulin fusion proteins and high affinity variants | |
JP5901084B2 (en) | Peptide adjuvant | |
KR20210010873A (en) | Artificial indiscriminate T helper cell epitope facilitating targeted antibody production with a limited T cell inflammatory response | |
MXPA01011130A (en) | Use of soluble costimulatory molecules to enhance immune responses | |
US20050255106A1 (en) | Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40 | |
BERGER et al. | o. 3 Vaccination strategy to treat persistent viral infections | |
WO2001085205A1 (en) | Compositions and methods for induction of active autoimmunity | |
WO2006089251A2 (en) | SYNERGISTIC EFFECT OF TGF-β BLOCKADE AND IMMUNOGENIC AGENTS ON TUMORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/011130 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-3964 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 2373256 Country of ref document: CA Ref country code: CA Ref document number: 2373256 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 616813 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017014170 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 515410 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/09376 Country of ref document: ZA Ref document number: 200109376 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 48257/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000930437 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008100381 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017014170 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000930437 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-3964 Country of ref document: CZ |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2001-3964 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000930437 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020017014170 Country of ref document: KR |